Compare Stocks: GOSS, PMN, CBUS, and EQ

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CBUS Cibus	$1.52 -1.6%	$1.72	$1.09 ▼ $4.19	$115.87M	1.59	400,769 shs	11,430 shs
EQ Equillium	$1.70 -3.1%	$2.26	$0.76 ▼ $3.54	$107.48M	1.81	614,157 shs	70,804 shs
GOSS Gossamer Bio	$11.31 +2.9%	$13.08	$9.10 ▼ $309.60	$33.13M	2	235,165 shs	62,678 shs
PMN Promis Neurosciences	$11.75 -9.2%	$13.88	$6.27 ▼ $27.40	$105.42M	-0.24	99,238 shs	18,654 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CBUS Cibus	-3.14%	+1.99%	-10.98%	+14.93%	+14.93%
EQ Equillium	-9.33%	-5.91%	-20.45%	-40.68%	+24.11%
GOSS Gossamer Bio	-5.99%	+0.27%	-21.50%	-16.84%	-95.54%
PMN Promis Neurosciences	-4.71%	+0.47%	-12.57%	+26.24%	+26.09%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CBUS Cibus	$1.52 -1.6%	$1.72	$1.09 ▼ $4.19	$115.87M	1.59	400,769 shs	11,430 shs
EQ Equillium	$1.70 -3.1%	$2.26	$0.76 ▼ $3.54	$107.48M	1.81	614,157 shs	70,804 shs
GOSS Gossamer Bio	$11.31 +2.9%	$13.08	$9.10 ▼ $309.60	$33.13M	2	235,165 shs	62,678 shs
PMN Promis Neurosciences	$11.75 -9.2%	$13.88	$6.27 ▼ $27.40	$105.42M	-0.24	99,238 shs	18,654 shs

7 Energy Stocks to Buy and Hold Forever

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CBUS Cibus	-3.14%	+1.99%	-10.98%	+14.93%	+14.93%
EQ Equillium	-9.33%	-5.91%	-20.45%	-40.68%	+24.11%
GOSS Gossamer Bio	-5.99%	+0.27%	-21.50%	-16.84%	-95.54%
PMN Promis Neurosciences	-4.71%	+0.47%	-12.57%	+26.24%	+26.09%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CBUS Cibus	2.00	Hold	$9.00	493.67% Upside
EQ Equillium	2.91	Moderate Buy	$7.57	346.69% Upside
GOSS Gossamer Bio	2.22	Hold	$256.00	2,164.28% Upside
PMN Promis Neurosciences	2.88	Moderate Buy	$34.00	189.34% Upside

Current Analyst Ratings Breakdown

Latest GOSS, PMN, CBUS, and EQ Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/21/2026	EQ Equillium	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
9/8/2026	PMN Promis Neurosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
9/4/2026	EQ Equillium	Roth Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$12.00
8/27/2026	GOSS Gossamer Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/27/2026	GOSS Gossamer Bio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/21/2026	PMN Promis Neurosciences	Roth Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$29.00
8/14/2026	GOSS Gossamer Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
8/11/2026	EQ Equillium	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
7/28/2026	PMN Promis Neurosciences	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$35.00 ➝ $69.00
7/28/2026	GOSS Gossamer Bio	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$80.00
7/27/2026	PMN Promis Neurosciences	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target	Buy	$20.00

(Data available from 9/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CBUS Cibus	$3.64M	31.83	N/A	N/A	$0.40 per share	3.79
EQ Equillium	N/A	N/A	N/A	N/A	$0.47 per share	N/A
GOSS Gossamer Bio	$48.47M	0.68	N/A	N/A	($42.43) per share	-0.27
PMN Promis Neurosciences	N/A	N/A	N/A	N/A	($0.58) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CBUS Cibus	-$127.08M	-$1.65	N/A	N/A	N/A	-2,258.89%	-287.03%	-27.99%	11/12/2026 (Estimated)
EQ Equillium	-$22.40M	-$0.20	N/A	N/A	N/A	N/A	-41.15%	-38.29%	11/12/2026 (Estimated)
GOSS Gossamer Bio	-$170.37M	-$56.00	N/A	N/A	N/A	-235.00%	N/A	-112.04%	11/4/2026 (Estimated)
PMN Promis Neurosciences	-$39.72M	-$8.54	N/A	N/A	N/A	N/A	-143.09%	-109.15%	11/11/2026 (Estimated)

Latest GOSS, PMN, CBUS, and EQ Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	CBUS Cibus	-$0.19	-$0.29	-$0.10	-$0.29	$1.70 million	$0.99 million
8/13/2026	Q2 2026	EQ Equillium	-$0.0540	-$0.04	+$0.0140	-$0.04	N/A	N/A
8/13/2026	Q2 2026	PMN Promis Neurosciences	-$1.38	-$1.28	+$0.10	-$1.28	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CBUS Cibus	N/A	N/A	N/A	N/A	N/A
EQ Equillium	N/A	N/A	N/A	N/A	N/A
GOSS Gossamer Bio	N/A	N/A	N/A	N/A	N/A
PMN Promis Neurosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CBUS Cibus	N/A	1.62	1.62
EQ Equillium	N/A	23.40	23.40
GOSS Gossamer Bio	N/A	0.53	0.53
PMN Promis Neurosciences	N/A	7.85	7.85

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CBUS Cibus	33.81%
EQ Equillium	27.05%
GOSS Gossamer Bio	81.23%
PMN Promis Neurosciences	50.13%

Insider Ownership

Company	Insider Ownership
CBUS Cibus	29.91%
EQ Equillium	17.84%
GOSS Gossamer Bio	4.15%
PMN Promis Neurosciences	1.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CBUS Cibus	118	76.43 million	53.57 million	Optionable
EQ Equillium	14	63.41 million	52.10 million	Not Optionable
GOSS Gossamer Bio	162	2.93 million	2.81 million	Optionable
PMN Promis Neurosciences	11	8.97 million	8.83 million	Not Optionable

GOSS, PMN, CBUS, and EQ Headlines

Recent News About These Companies

Promis Neurosciences (NASDAQ:PMN) Stock Price Down 0.4% - Should You Sell?

September 23 at 2:01 AM | americanbankingnews.com

Promis Neurosciences (NASDAQ:PMN) Trading Down 0.4% - Should You Sell?

September 23 at 1:59 AM | marketbeat.com

ProMIS Neurosciences to Participate in Upcoming Conferences and Events in September

September 1, 2026 | globenewswire.com

Promis Neurosciences (NASDAQ:PMN) Receives Average Recommendation of "Moderate Buy" from Analysts

September 1, 2026 | marketbeat.com

Analysts Offer Insights on Healthcare Companies: Hims & Hers Health (HIMS) and ProMIS Neurosciences (PMN)

August 22, 2026 | theglobeandmail.com

ProMIS Neurosciences Inc.: ProMIS Neurosciences Announces Second Quarter 2026 Financial Results and Provides Corporate Highlights

August 13, 2026 | finanznachrichten.de

ProMIS Neurosciences Announces Second Quarter 2026 Financial Results and Provides Corporate Highlights

August 13, 2026 | globenewswire.com

Vertex Pharmaceuticals Inc (VRTX) (Q2 2026) Earnings Call Highlights: Revenue Surges 12% to $3.3 Billion, Driven by CF Portfolio and New Product Momentum

August 4, 2026 | gurufocus.com

ProMIS Neurosciences to Report Second Quarter 2026 Financial Results and Business Update on August 13, 2026

August 3, 2026 | globenewswire.com

Small-Cap ProMIS Neurosciences Says Lead Drug Shows Encouraging Action in Early Alzheimer's Study

July 28, 2026 | benzinga.com

ProMIS Neurosciences Reports Positive Blinded Six-Month Interim Safety and Biomarker Data for PMN310 in the PRECISE-AD Phase 1b Alzheimer’s Disease Trial

July 28, 2026 | markets.businessinsider.com

ProMIS Neurosciences Reports Positive Blinded Six-Month Interim Safety and Biomarker Data for PMN310 in the PRECISE-AD Phase 1b Alzheimer's Disease Trial

July 28, 2026 | globenewswire.com

ProMIS Neurosciences Inc.: ProMIS Neurosciences to Host Webinar to Discuss Upcoming 6-Month Blinded Interim Data from PRECISE-AD Phase 1b Trial of PMN310 in Alzheimer's Disease

July 27, 2026 | finanznachrichten.de

ProMIS Neurosciences to Host Webinar to Discuss Upcoming 6-Month Blinded Interim Data from PRECISE-AD Phase 1b Trial of PMN310 in Alzheimer’s Disease

July 27, 2026 | markets.businessinsider.com

ProMIS Neurosciences to Host Webinar to Discuss Upcoming 6-Month Blinded Interim Data from PRECISE-AD Phase 1b Trial of PMN310 in Alzheimer's Disease

July 27, 2026 | globenewswire.com

PMN310 cuts Alzheimer oligomers in humans, dodging side effects that limit rival drugs

July 15, 2026 | msn.com

ProMIS Neurosciences Reports First Human Evidence of Amyloid-Beta Oligomer Target Engagement by PMN310 at AAIC 2026

July 14, 2026 | globenewswire.com

ProMIS Neurosciences Inc.

July 8, 2026 | cnn.com

Analysts Offer Insights on Healthcare Companies: ProMIS Neurosciences (PMN) and Icon (ICLR)

July 1, 2026 | theglobeandmail.com

Wall Street Analysts See a 230.23% Upside in Promis Neurosciences (PMN): Can the Stock Really Move This High?

June 30, 2026 | zacks.com

All You Need to Know About Promis Neurosciences (PMN) Rating Upgrade to Buy

June 12, 2026 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

GOSS, PMN, CBUS, and EQ Company Descriptions

Cibus NASDAQ:CBUS

$1.52 -0.02 (-1.56%)

As of 10:56 AM Eastern

Cibus, Inc., a agricultural biotechnology company, develops and licenses plant traits to seed companies for royalties. The company primarily focus on trait productivity in two areas, including productivity traits that enable farmers to have higher yields and reduce the use of the crop protection chemicals and fertilizers; and sustainable ingredients that enable corporations to replace ingredients that are fossil fuel based or whose production results in increased greenhouse gases. Cibus, Inc. is based in San Diego, California.

Equillium NASDAQ:EQ

$1.70 -0.06 (-3.14%)

As of 11:04 AM Eastern

Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications. In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.

Gossamer Bio NASDAQ:GOSS

$11.31 +0.32 (+2.88%)

As of 11:03 AM Eastern

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.

Promis Neurosciences NASDAQ:PMN

$11.75 -1.19 (-9.19%)

As of 11:01 AM Eastern

ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates comprise of PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest GOSS, PMN, CBUS, and EQ Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest GOSS, PMN, CBUS, and EQ Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

GOSS, PMN, CBUS, and EQ Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

GOSS, PMN, CBUS, and EQ Company Descriptions

Cibus NASDAQ:CBUS

Equillium NASDAQ:EQ

Gossamer Bio NASDAQ:GOSS

Promis Neurosciences NASDAQ:PMN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest GOSS, PMN, CBUS, and EQ Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest GOSS, PMN, CBUS, and EQ Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

GOSS, PMN, CBUS, and EQ Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

GOSS, PMN, CBUS, and EQ Company Descriptions

Cibus NASDAQ:CBUS

Equillium NASDAQ:EQ

Gossamer Bio NASDAQ:GOSS

Promis Neurosciences NASDAQ:PMN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools